Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial

BACKGROUND: Residual breast cancer after neo-adjuvant chemotherapy (NACT) predicts disease outcome and is a surrogate for survival in aggressive breast cancer (BC) subtypes. Pathological complete response (pCR) rate, however, is lower for luminal B BC in comparison to the triple negative (TNBC) and...

Descripción completa

Detalles Bibliográficos
Autores principales: De Caluwé, Alex, Buisseret, Laurence, Poortmans, Philip, Van Gestel, Dirk, Salgado, Roberto, Sotiriou, Christos, Larsimont, Denis, Paesmans, Marianne, Craciun, Ligia, Stylianos, Drisis, Vandekerckhove, Christophe, Reyal, Fabien, Isabelle, Veys, Eiger, Daniel, Piccart, Martine, Romano, Emanuela, Ignatiadis, Michail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343924/
https://www.ncbi.nlm.nih.gov/pubmed/34362344
http://dx.doi.org/10.1186/s12885-021-08601-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343924/
https://www.ncbi.nlm.nih.gov/pubmed/34362344
http://dx.doi.org/10.1186/s12885-021-08601-1

Ejemplares similares